It has been reported that, like genetic and pharmacological inhibition of BCKDK, treating triple-negative breast cancer (TNBC) cells with doxorubicin downregulated BCKDK expression, reducing the intracellular concentrations of BCKAs. The gene discussed is BCKDK; the disease is triple-negative breast carcinoma.